Skip to main content

Day: April 23, 2021

CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants

Written by Customer Service on . Posted in Public Companies.

Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it completed an additional potentially non-dilutive convertible debt offering with an institutional investor, which provides $25 million of immediately available capital. The note has a two-year maturity, bears interest at the rate of 10% per annum and is secured by all assets of the Company, excluding its intellectual property. The note may be converted at the option of the investor into shares of the Company’s common stock at a conversion price of $10.00 per share. Chris Recknor, M.D.,...

Continue reading

Profire Energy Sets First Quarter 2021 Conference Call for Thursday, May 6, 2021 at 1:00 p.m. ET

Written by Customer Service on . Posted in Public Companies.

LINDON, Utah, April 22, 2021 (GLOBE NEWSWIRE) — Profire Energy, Inc. (NASDAQ: PFIE), a technology company (the “Company”) that provides solutions which enhance the efficiency, safety, and reliability of industrial combustion appliances, will hold a conference call on Thursday, May 6, 2021 at 1:00 p.m. ET to discuss results for its 2021 first quarter ended March 31, 2021. Financial results are expected to be filed with the Securities and Exchange Commission and reported in a press release prior to the conference call. Profire Energy Co-CEO and CFO Ryan Oviatt and Co-CEO Cameron Tidball will host the presentation, followed by a question and answer period. Date: Thursday, May 6, 2021Time: 1:00 p.m. ET (11:00 a.m. MT)Toll-free dial-in number: 1-855-327-6837International dial-in number: 1-631-891-4304 The conference call...

Continue reading

UPDATE – Treace Medical Concepts Announces Pricing of Upsized Initial Public Offering

Written by Customer Service on . Posted in Public Companies.

PONTE VEDRA, Fla., April 22, 2021 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the pricing of its upsized initial public offering of an aggregate of 11,250,000 shares of its common stock, 6,250,000 of which are being sold by Treace and 5,000,000 of which are being sold by certain selling stockholders, at a public offering price of $17.00 per share. The gross proceeds from the offering to Treace are expected to be approximately $106.3 million before deducting underwriting discounts and commissions and other offering expenses payable by Treace. Treace will not receive any proceeds from the sale of shares by the selling stockholders. In...

Continue reading

Treace Medical Concepts Announces Pricing of Upsized Initial Public Offering

Written by Customer Service on . Posted in Public Companies.

PONTE VEDRA, Fla., April 22, 2021 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the pricing of its upsized initial public offering of an aggregate of 11,250,000 shares of its common stock, 6,250,000 of which are being sold by Treace and 5,000,000 of which are being sold by certain selling stockholders, at a public offering price of $17.00 per share. The gross proceeds from the offering to Treace are expected to be approximately $106.3 million before deducting underwriting discounts and commissions and other offering expenses payable by Treace. Treace will not receive any proceeds from the sale of shares by the selling stockholders. In...

Continue reading

Camposol Holding PLC Invitation to the Presentation of Fourth Quarter and Audited Full Year 2020 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Camposol Holding PLC will announce the results for the full year 2020 on Thursday, April 29, 2021. In connection with the release, a telephone conference will be held at 9:30 a.m. (Lima) as described below. The presentation will be published at 8:30 a.m. (Lima) and will be available on the Company’s website. In connection with the earnings release Samuel Dyer Coriat, CEO, and Andrés Colichón Sas, CFO, will host a conference call presentation and a Q&A session at 9:30 a.m. (Lima). To participate in the conference call, please use the following numbers: London, UK Local                                              +0800 028 8438 US/Canada International                                   +1 409 981 0728 Zurich, Switzerland, Local                                 +044 580 1740 Oslo, Norway, Local                                          +47...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.